# Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

> **NCT00761449** · PHASE2 · COMPLETED · sponsor: **Nordic MDS Group** · enrollment: 28 (actual)

## Conditions studied

- MDS
- AML

## Interventions

- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00761449
- **Lead sponsor:** Nordic MDS Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761449, "Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00761449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*